Nerve Growth Factor Study
Evaluation of the Pain Alleviating Effects of NV-01 in Dogs Suffering from Osteoarthritis-Associated Pain
We are seeking participants for a trial of a new biological compound, an antibody, that is being used to treat pain. It is a canine version of a compound being tested for arthritis pain control in humans. The medication is NOT a non-steroidal anti-inflammatory (NSAID), and will administered once with an expected duration of effect of several weeks.
Description: The purpose of this study is to evaluate the efficacy of NV-01, an antibody to nerve growth factor, for the treatment of osteoarthritis pain in dogs. This is a blinded, placebo controlled, pilot study. Twenty four dogs will be recruited into this study. Each dog will be evaluated over an 8 week period for changes in pain and mobility using various owner assessments, activity monitors, kinetic variables and veterinarian-assessed joint pain.
Dogs must satisfy the following criteria:
- Must have decreased mobility due to painful osteoarthritis.
- Be at least 1 year of age and weigh more than 15 kg (33 lbs).
Dogs with the following conditions will be excluded:
- Other conditions that may be causing immobility or pain (neurological disease, surgical altercation, L-S pain).
- Concurrent diseases and conditions including, but not limited to, cardiovascular disease, renal disease, liver disease, neoplasia, UTI, hypothyroidism, diabetes mellitus or infectious disease.
We need owners of dogs to be able to commit to the following:
Study incentives: The study will cover the cost of the examination, hospitalization, blood work and urinalysis, radiographs, and study drug. No other financial incentives are offered for participation.
Comparative Pain Research Laboratory at North Carolina State University, College of Veterinary Medicine (919) 513-6853 or email firstname.lastname@example.org